scholarly journals Baculovirus Capsid Display

2003 ◽  
Vol 8 (5) ◽  
pp. 702
Keyword(s):  
Capsid Display

scholarly journals Progress in Adenoviral Capsid-Display Vaccines

Biomedicines ◽  
2018 ◽  
Vol 6 (3) ◽  
pp. 81 ◽  
Author(s):  
Marija Vujadinovic ◽  
Jort Vellinga
Keyword(s):  
Immune Responses ◽  
Adenoviral Vector ◽  
Vaccine Development ◽  
Adenoviral Vectors ◽  
Manufacturing Costs ◽  
Genetic Vaccine ◽  
Immunogenic Peptides ◽  
T Cell Immune Responses ◽  
Protein Ix ◽  
Capsid Display

Adenoviral vectored vaccines against infectious diseases are currently in clinical trials due to their capacity to induce potent antigen-specific B- and T-cell immune responses. Heterologous prime-boost vaccination with adenoviral vector and, for example, adjuvanted protein-based vaccines can further enhance antigen-specific immune responses. Although leading to potent immune responses, these heterologous prime-boost regimens may be complex and impact manufacturing costs limiting efficient implementation. Typically, adenoviral vectors are engineered to genetically encode a transgene in the E1 region and utilize the host cell machinery to express the encoded antigen and thereby induce immune responses. Similarly, adenoviral vectors can be engineered to display foreign immunogenic peptides on the capsid-surface by insertion of antigens in capsid proteins hexon, fiber and protein IX. The ability to use adenoviral vectors as antigen-display particles, with or without using the genetic vaccine function, greatly increases the versatility of the adenoviral vector for vaccine development. This review describes the application of adenoviral capsid antigen-display vaccine vectors by focusing on their distinct advantages and possible limitations in vaccine development.

scholarly journals Adenovirus capsid-display of the retro-oriented human complement inhibitor DAF reduces Ad vector–triggered immune responses in vitro and in vivo

Blood ◽  
2010 ◽  
Vol 116 (10) ◽  
pp. 1669-1677 ◽  
Author(s):  
Sergey S. Seregin ◽  
Yasser A. Aldhamen ◽  
Daniel M. Appledorn ◽  
Zachary C. Hartman ◽  
Nathaniel J. Schuldt ◽  
...  
Keyword(s):  
Gene Transfer ◽  
Immune Responses ◽  
Cell Activation ◽  
Innate Immune ◽  
Complement Inhibitor ◽  
Human Complement ◽  
Endothelial Cell Activation ◽  
Capsid Display

Abstract Adenovirus (Ad) vectors are widely used in human clinical trials. However, at higher dosages, Ad vector–triggered innate toxicities remain a major obstacle to many applications. Ad interactions with the complement system significantly contribute to innate immune responses in several models of Ad-mediated gene transfer. We constructed a novel class of Ad vectors, genetically engineered to “capsid-display” native and retro-oriented versions of the human complement inhibitor decay-accelerating factor (DAF), as a fusion protein from the C-terminus of the Ad capsid protein IX. In contrast to conventional Ad vectors, DAF-displaying Ads dramatically minimized complement activation in vitro and complement-dependent immune responses in vivo. DAF-displaying Ads did not trigger thrombocytopenia, minimized endothelial cell activation, and had diminished inductions of proinflammatory cytokine and chemokine responses. The retro-oriented display of DAF facilitated the greatest improvements in vivo, with diminished activation of innate immune cells, such as dendritic and natural killer cells. In conclusion, Ad vectors can capsid-display proteins in a manner that not only retains the functionality of the displayed proteins but also potentially can be harnessed to improve the efficacy of this important gene transfer platform for numerous gene transfer applications.

scholarly journals Baculoviral capsid display of His-tagged ZnO inorganic binding peptide

2010 ◽  
Vol 62 (2) ◽  
pp. 133-141 ◽  
Author(s):  
Lei Song ◽  
Yingying Liu ◽  
Jinchun Chen
Keyword(s):  
Binding Peptide ◽  
Capsid Display

Baculovirus capsid display in vaccination schemes: effect of a previous immunity against the vector on the cytotoxic response to delivered antigens

2018 ◽  
Vol 102 (23) ◽  
pp. 10139-10146
Author(s):  
Paula Molinari ◽  
Guido N. Molina ◽  
Eugenia Tavarone ◽  
María Paula Del Médico Zajac ◽  
Gabriel Morón ◽  
...  
Keyword(s):  
Cytotoxic Response ◽  
Capsid Display

scholarly journals A Replicating Adenovirus Capsid Display Recombinant Elicits Antibodies against Plasmodium falciparum Sporozoites in Aotus nancymaae Monkeys

2014 ◽  
Vol 83 (1) ◽  
pp. 268-275 ◽  
Author(s):  
Kasey A. Karen ◽  
Cailin Deal ◽  
Robert J. Adams ◽  
Carolyn Nielsen ◽  
Cameron Ward ◽  
...  
Keyword(s):  
Plasmodium Falciparum ◽  
Neutralizing Antibodies ◽  
Cell Epitope ◽  
Intratracheal Instillation ◽  
New World Monkeys ◽  
Content Type ◽  
Human Adenoviruses ◽  
Novel Approach ◽  
Capsid Display

Decades of success with live adenovirus vaccines suggest that replication-competent recombinant adenoviruses (rAds) could serve as effective vectors for immunization against other pathogens. To explore the potential of a live rAd vaccine against malaria, we prepared a viable adenovirus 5 (Ad5) recombinant that displays a B-cell epitope from the circumsporozoite protein (CSP) ofPlasmodium falciparumon the virion surface. The recombinant inducedP. falciparumsporozoite-neutralizing antibodies in mice. Human adenoviruses do not replicate in mice. Therefore, to examine immunogenicity in a system in which, as in humans, the recombinant replicates, we constructed a similar recombinant in an adenovirus mutant that replicates in monkey cells and immunized fourAotus nancymaaemonkeys. The recombinant replicated in the monkeys after intratracheal instillation, the first demonstration of replication of human adenoviruses in New World monkeys. Immunization elicited antibodies both to thePlasmodiumepitope and the Ad5 vector. Antibodies from all four monkeys recognized CSP on intact parasites, and plasma from one monkey neutralized sporozoitesin vitroand conferred partial protection againstP. falciparumsporozoite infection after passive transfer to mice. Prior enteric inoculation of two animals with antigenically wild-type adenovirus primed a response to the subsequent intratracheal inoculation, suggesting a route to optimizing performance. A vaccine is not yet available againstP. falciparum, which induces the deadliest form of malaria and kills approximately one million children each year. The live capsid display recombinant described here may constitute an early step in a critically needed novel approach to malaria immunization.

scholarly journals Baculovirus Capsid Display Potentiates OVA Cytotoxic and Innate Immune Responses

PLoS ONE ◽  
2011 ◽  
Vol 6 (8) ◽  
pp. e24108 ◽  
Author(s):  
Paula Molinari ◽  
María I. Crespo ◽  
María J. Gravisaco ◽  
Oscar Taboga ◽  
Gabriel Morón
Keyword(s):  
Immune Responses ◽  
Innate Immune ◽  
Innate Immune Responses ◽  
Capsid Display

scholarly journals Antigen capsid-display on human adenovirus 35 via pIX fusion is a potent vaccine platform

PLoS ONE ◽  
2017 ◽  
Vol 12 (3) ◽  
pp. e0174728 ◽  
Author(s):  
Nadine C. Salisch ◽  
Marija Vujadinovic ◽  
Esmeralda van der Helm ◽  
Dirk Spek ◽  
Lars Vorthoren ◽  
...  
Keyword(s):  
Human Adenovirus ◽  
Vaccine Platform ◽  
Capsid Display

scholarly journals Apropos of Universal Epitope Discovery for COVID-19 Vaccines: A Framework for Targeted Phage Display-Based Delivery and Integration of New Evaluation Tools

2021 ◽  
Author(s):  
Christopher Markosian ◽  
Daniela I. Staquicini ◽  
Prashant Dogra ◽  
Esteban Dodero-Rojas ◽  
Fenny H. F. Tang ◽  
...  
Keyword(s):  
Phage Display ◽  
Broad Spectrum ◽  
Spike Protein ◽  
Evaluation Tools ◽  
Vaccine Candidates ◽  
Phage Capsid ◽  
Universal Epitope ◽  
Epitope Discovery ◽  
Capsid Display

AbstractTargeted bacteriophage (phage) particles are potentially attractive yet inexpensive platforms for immunization. Herein, we describe targeted phage capsid display of an immunogenically relevant epitope of the SARS-CoV-2 Spike protein that is empirically conserved, likely due to the high mutational cost among all variants identified to date. This observation may herald an approach to developing vaccine candidates for broad-spectrum, towards universal, protection against multiple emergent variants of coronavirus that cause COVID-19.

scholarly journals Baculovirus capsid display: a novel tool for transduction imaging

2003 ◽  
Vol 8 (5) ◽  
pp. 853-862 ◽  
Author(s):  
Sari P. Kukkonen ◽  
Kari J. Airenne ◽  
Varpu Marjomäki ◽  
Olli H. Laitinen ◽  
Pauliina Lehtolainen ◽  
...  
Keyword(s):  
Capsid Display
Sign in / Sign up

Export Citation Format

Share Document